SteadyMed Ltd. (STDY) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results
November 12, 2015 4:17 PM ESTSAN RAMON, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced recent developments and financial results for the third quarter ended September 30, 2015.
"SteadyMed continued to make significant progress in executing across several strategic initiatives during and subsequent to the third quarter. As expected, we recently began production of registration stability lots for our lead drug product candidate Trevyent®, for the treatment of pulmonary arterial hypertension (PAH). We expect to have the... More
SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results
November 12, 2015 4:17 PM ESTSAN RAMON, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced recent developments and financial results for the third quarter ended September 30, 2015.
"SteadyMed continued to make significant progress in executing across several strategic initiatives during and subsequent to the third quarter. As expected, we recently began production of registration stability lots for our lead drug product candidate Trevyent®, for the treatment of pulmonary arterial hypertension (PAH). We expect to have the... More
